Codexis expands use of its Proprietary Molecular Breeding technology
Privately held biotechnology company, Codexis has expanded its collaborative programmes by signing agreements with Indian generic pharmaceutical company, Arch Pharmalabs and India\'s Matrix Laboratories, a provider of active pharmaceutical ingredients.
Privately held biotechnology company, Codexis has expanded its collaborative programmes by signing agreements with Indian generic pharmaceutical company, Arch Pharmalabs and India's Matrix Laboratories, a provider of active pharmaceutical ingredients.
Under the terms of the new agreement with Matrix, Codexis will employ its proprietary MolecularBreeding technology to develop a novel synthetic process for the Matrix product using a Codexis ThoroughBred biocatalyst. The process will be transferred to Matrix for final scale-up and manufacturing, and Matrix will receive exclusive manufacturing and marketing rights to the novel process being developed. Codexis will receive R&D funding, milestone payments and ongoing commercial payments on sales of the product.
Codexis has granted to Arch a non-exclusive license to the proprietary biocatalytic system and will transfer the process to Arch in exchange for upfront and milestone payments. It will supply Arch with the ThoroughBred catalyst for the manufacture a pharmaceutical intermediate. Codexis will directly market and sell the intermediate to the generic pharmaceutical industry.
Earlier this month, Codexis achieved the second technical milestone in its therapeutics research collaboration with Pfizer. This achievement triggered a second milestone payment from Pfizer since June.
The collaboration applies Codexis' proprietary process research and development platform to some of Pfizer's small molecule therapeutics and rapidly generates novel biocatalysts for the manufacture of Pfizer's products, improving R&D productivity while reducing manufacturing costs.
